Invitation

Dear colleagues,

On behalf of Bristol-Myers Squibb, it is my pleasure to invite you to an industry satellite symposium entitled “Immuno-Oncology: Current Developments and Clinical Directions in Lung and Head & Neck Cancers,” as part of the ESMO 2016 Congress taking place in Copenhagen, Denmark.

In this symposium, we will discuss the role of the immune system in oncology and highlight the latest research evaluating the use of immuno-oncology therapies, as monotherapy or in combination, as treatment modalities in lung and head & neck cancers.

Emerging data from novel agents that modulate immune checkpoint pathways in patients with cancer support additional study, with many of these agents having safety and efficacy data, including survival, in both lung cancer and head & neck cancer. Furthermore, research is continuing to elucidate the relevance of biomarkers in both lung and head & neck cancers.

Other topics will include clinical considerations for use of immune checkpoint inhibitors such as management of immune-related adverse reactions and ongoing efforts in early-stage cancer research. We anticipate that the high levels of interaction and analysis provided by the symposium will inform and benefit your clinical practice and knowledge of ongoing research efforts, and look forward to welcoming you in Copenhagen.

Martin Reck, MD, PhD
LungenClinic, Germany
Meeting Chair

Programme

13:00
Welcome and Introductions
Martin Reck, MD, PhD
Germany

13:10
Clinical Update for I-O in Lung Cancer
Martin Reck, MD, PhD
Germany

13:30
Emerging Data for Use of I-O Agents as Potential Treatment Options in H&N Cancer
Joël Guigay, MD, PhD
France

13:50
Clinical Considerations for I-O and Future Approaches
Solange Peters, MD, PhD
Switzerland

14:10
Close and Outlook
Martin Reck, MD, PhD
Germany

14:15
Audience Q&A
Full Panel

Sunday, 9 October 2016 | 13:00–14:30
Bella Center
Stockholm Auditorium
Copenhagen, Denmark